Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY2 | P41231 | 4/20 | 0.62 |
| ▸ | P2RY4 | P51582 | 4/20 | 0.62 |
| ▸ | P2RY6 | Q15077 | 3/20 | 0.62 |
| ▸ | POLB | P06746 | 2/20 | 0.62 |
| ▸ | FUT5 | Q11128 | 1/20 | 0.53 |
| ▸ | F2 | P00734 | 2/20 | 0.52 |
| ▸ | TGM2 | P21980 | 1/20 | 0.47 |
| ▸ | TERT | O14746 | 1/20 | 0.47 |
| ▸ | NT5E | P21589 | 2/20 | 0.47 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29702417 | 1.00 | P2RY2 (0.62) | P2RY2P2RY4P2RY6POLBFUT5 | |
| SCHEMBL29424735 | 1.00 | P2RY2 (0.62) | P2RY2P2RY4P2RY6POLBFUT5 | |
| SCHEMBL29365434 | 1.00 | P2RY2 (0.62) | P2RY2P2RY4P2RY6POLBFUT5 | |
| SCHEMBL29371610 | 1.00 | P2RY2 (0.62) | P2RY2P2RY4P2RY6POLBFUT5 | |
| SCHEMBL29551697 | 0.96 | P2RY2 (0.61) | P2RY2P2RY4P2RY6POLBFUT5 | |
| SCHEMBL29365163 | 0.96 | P2RY2 (0.61) | P2RY2P2RY4P2RY6POLBFUT5 | |
| SCHEMBL8613676 | 0.95 | P2RY2 (0.62) | P2RY2P2RY4P2RY6POLBFUT5 | |
| SCHEMBL8614074 | 0.95 | P2RY2 (0.62) | P2RY2P2RY4P2RY6POLBFUT5 | |
| SCHEMBL15698310 | 0.95 | P2RY2 (0.56) | P2RY2P2RY4P2RY6POLBFUT5 | |
| SCHEMBL30839331 | 0.95 | P2RY2 (0.57) | P2RY2P2RY4P2RY6POLBFUT5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240173390-A1 | PEPTIDE VACCINE FORMULATIONS AND USE THEREOF FOR INDUCING AN IMMUNE RESPONSE | THE U.S.A, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2024-05-30 | — | — | US | disclosed |
| US-11938177-B2 | Peptide vaccine formulations and use thereof for inducing an immune response | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2024-03-26 | — | — | US | disclosed |
| US-20230026627-A1 | Compositions and Methods of Manufacturing Star Polymers for Ligand Display and/or Drug Delivery | VACCITECH NORTH AMERICA, INC. (US) | 2023-01-26 | — | — | US | disclosed |
| US-20220152170-A1 | PEPTIDE VACCINE FORMULATIONS AND USE THEREOF FOR INDUCING AN IMMUNE RESPONSE | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVIC (US) | 2022-05-19 | — | — | US | disclosed |
| EP-3955964-A1 | COMPOSITIONS AND METHODS OF MANUFACTURING STAR POLYMERS FOR LIGAND DISPLAY AND/OR DRUG DELIVERY | Avidea Technologies, Inc. (US) | 2022-02-23 | — | — | EP | disclosed |
| US-11191821-B2 | Peptide vaccine formulations and use thereof for inducing an immune response | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2021-12-07 | — | — | US | disclosed |
| US-20210353740-A1 | HIV-1 ENV FUSION PEPTIDE NANOPARTICLE CARRIER CONJUGATES AND THEIR USE | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVIC (US) | 2021-11-18 | — | — | US | disclosed |
| US-20210128727-A1 | A pharmaceutical combination for use in the treatment of cancer | UNIVERSITÄTSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITÄT MAINZ (DE) | 2021-05-06 | — | — | US | disclosed |
| EP-3790582-A1 | A PHARMACEUTICAL COMBINATION FOR USE IN THE TREATMENT OF CANCER | Universitätsmedizin der Johannes Gutenberg-Universität Mainz (DE) | 2021-03-17 | — | — | EP | disclosed |
| US-20210023208-A1 | EXPRESSION VECTOR DELIVERY SYSTEM AND USE THEREOF FOR INDUCING AN IMMUNE RESPONSE | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVIC (US) | 2021-01-28 | — | — | US | disclosed |
| EP-1567863-A4 | METHODS OF THERAPY AND DIAGNOSIS | NUVELO INC (US) | 2007-10-03 | — | — | EP | disclosed |
| EP-1483407-A4 | METHODS OF THERAPY AND DIAGNOSIS | NUVELO INC (US) | 2006-11-15 | — | — | EP | disclosed |
| US-20050281813-A1 | Methods of therapy and diagnosis using targeting of cells that express toll-like receptor proteins | NUVELO, INC. (US) | 2005-12-22 | — | — | US | disclosed |
| EP-1567863-A2 | METHODS OF THERAPY AND DIAGNOSIS | Nuvelo, Inc. (US) | 2005-08-31 | — | — | EP | disclosed |
| WO-2005052126-A2 | BIOLOGICALLY ACTIVE ANTIBODIES RECOGNIZING A CELL SURFACE MOLECULE SELECTIVELY EXPRESSED ON LIVING MOUSE NATURAL TYPE ONE (I) INTERFERON PRODUCING CELLS | WASHINGTON UNIVERSITY IN ST. LOUIS (US) | 2005-06-09 | — | — | WO | disclosed |
| EP-1483407-A2 | METHODS OF THERAPY AND DIAGNOSIS | Nuvelo, Inc. (US) | 2004-12-08 | — | — | EP | disclosed |
| WO-2004047612-A2 | METHODS OF THERAPY AND DIAGNOSIS | NUVELO, INC. (US) | 2004-06-10 | — | — | WO | disclosed |
| US-20040023870-A1 | Methods of therapy and diagnosis using targeting of cells that express toll-like receptor proteins | NUVELO, A CORP. OF NEVADA | 2004-02-05 | — | — | US | disclosed |
| US-20040022786-A1 | Methods of therapy and diagnosis using targeting of cells that express toll-like receptor proteins | DEDEA DOUGLAS (US) | 2004-02-05 | — | — | US | disclosed |
| WO-2003068935-A2 | METHODS OF THERAPY AND DIAGNOSIS | NUVELO, INC. (US) | 2003-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240173390-A1 | PEPTIDE VACCINE FORMULATIONS AND USE THEREOF FOR INDUCING AN IMMUNE RESPONSE | NGLY1, MYD88, SPPL2B | P2RY2 4631/4885P2RY4 4468/4885P2RY6 4268/4885 |
| US-11938177-B2 | Peptide vaccine formulations and use thereof for inducing an immune response | NGLY1, MYD88, SPPL2B | P2RY2 4631/4885P2RY4 4468/4885P2RY6 4268/4885 |
| US-11191821-B2 | Peptide vaccine formulations and use thereof for inducing an immune response | NGLY1, MYD88, SPPL2B | P2RY2 4631/4885P2RY4 4468/4885P2RY6 4268/4885 |
| US-20230026627-A1 | Compositions and Methods of Manufacturing Star Polymers for Ligand Display and/or Drug Delivery | TNFSF10, SELPLG, FCGRT | P2RY2 219/4885P2RY4 141/4885P2RY6 174/4885 |
| US-20220152170-A1 | PEPTIDE VACCINE FORMULATIONS AND USE THEREOF FOR INDUCING AN IMMUNE RESPONSE | NGLY1, MYD88, SPPL2B | P2RY2 4631/4885P2RY4 4468/4885P2RY6 4268/4885 |
| US-20210023208-A1 | EXPRESSION VECTOR DELIVERY SYSTEM AND USE THEREOF FOR INDUCING AN IMMUNE RESPONSE | CD69, CD14, CD4 | P2RY2 3411/4885P2RY4 3954/4885P2RY6 2403/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.